Paris-Based One Biosciences Secures €15M In Series A Round

Founded in 2020 by Dr. Céline Vallot, Curie Institute, and Home Biosciences, the company helps clinicians choose the best treatments by decoding tumour heterogeneity from standard clinical samples. It also supports pharma companies in improving clinical trial outcomes.

Their technology builds detailed functional profiles of patient tumours, offering insights that can improve clinical decisions, patient selection, and therapy development.

Read Also - German Photonic Processing Scale-up Q.ANT Secures €62M In Series A Round

One Biosciences partners with the Curie Institute, Gustave Roussy Institute, and AP-HP, and is supported by Medicen, PSCC, and Matwin.

Hedi Ben Brahim, CEO of One Biosciences, said: “This funding enables us to translate our breakthrough single-cell technology into real-time insights that could directly inform physician decision-making, improve patient care, and accelerate drug development.

The extraordinary support we have received from this group of leading global investors reinforces our conviction and fast-tracks our route to market.”

Dr Céline Vallot, Co-Founder of One Biosciences and group leader at Curie Institute commented: “This investment coupled with our established capacity to train our AI algorithms with proprietary single-cell patient datasets will further substantiate our ability to predict the response to most classes of oncology therapeutics from clinical-grade specimens.”

The funding round was co-led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Polytechnique Ventures, and Kima Ventures.

The funds will be used to advance clinical development of One Biosciences’ flagship OneMap™ platform and to scale partnerships with pharma and biotech companies.

About One Biosciences

Founded in 2020, One Biosciences uses single-cell analysis to discover new drug targets and precision therapies for hard-to-treat diseases. With a strong in-house computational team, it runs an integrated discovery platform. The company is backed by Institut Curie and Home Biosciences.